



CANCER CONSORTIUM

FRED HUTCH • UNIVERSITY OF WASHINGTON • SEATTLE CHILDREN'S

SURVIVORSHIP PILOT AWARD

The Cancer Consortium Survivorship Program (<https://www.fredhutch.org/survivorship>) invites proposals of high impact and innovation that will promote new research directions focused on cancer survivors. The goal of this award is to stimulate cross-institutional collaborations (Fred Hutch, UW, Seattle Children's) and/or new collaborations between Consortium investigators who have not previously worked together.

Per the National Cancer Institute: **Survivorship** focuses on the health and well-being of a person with cancer from the time of diagnosis until the end of life. This includes the physical, mental, emotional, social, and financial effects of cancer that begin at diagnosis and continue through treatment and beyond. The survivorship experience also includes issues related to follow-up care (including regular health and wellness checkups), late effects of treatment, cancer recurrence, second cancers, and quality of life. Family members, friends, and caregivers are also considered part of the survivorship experience. However, for the purposes of this application, projects that focus on timepoints at time of cancer diagnosis and treatment will be accepted only if they are clearly linked to a long-term health or psychosocial outcome. Health services research proposals otherwise meeting these criteria are also welcome.

Please reach out to Dr. Eric Chow (ericchow@uw.edu) with any questions.

Funding details: Up to \$50,000 direct costs over 1 year, to begin August 1, 2023. Payment of indirect costs is not allowed for this award.

Due Date: May 1, 2023; awardees will be announced no later than June 1, 2023.

Eligibility Criteria: 1) Applications must either center on cross-institutional collaborations (investigators with primary appointments at different Consortium partners) and/or new collaborations (which can be among investigators based at the same Consortium partner but who have no previously co-funded work and no significant non-funded prior collaborations). 2) At least one of the primary investigators should be a Cancer Consortium investigator (<https://www.cancerconsortium.org/membership.html>). 3) Priority will be given to investigators who have not previously received a Survivorship Pilot award. 4) A member of the application team may be asked to pitch their proposal at the May 12, 2023 Survivorship Research Symposium (10am – 3pm; please RSVP at: <https://fredhutch.org/survivorship2023>)

Application Details: Submit as a PDF file labeled with your last names and shortened title containing the following information to Ms. Emily Artim (erajotte@fredhutch.org)

- Project Title, Investigator Names, Institutional Positions, with brief explanation of how this represents a cross-institutional collaboration and/or new collaboration
- Proposal (limited to 2 pages, NIH formatting rules), including as appropriate: Background (i.e., significance/innovation), Aims and Hypotheses, Approach (any preliminary data [not required], study design, statistical considerations [highly encouraged]), and Future Plans (i.e., how will this award lead to new grants)
- Any tables and figures (limited to 1 additional page)
- References (limited to 1 additional page)
- Investigator biosketches (NIH format)

Budget: A budget should also be included, including any other funding sources that may be available to support part of the proposed work (if applicable). Funds may be spent on salary, supplies, shared resources, etc. Subawards will not be allowed, but if applicants are from different Consortium institutions, funds specific to each institution may be provided.

Deliverables:

- Progress report due at 1-year (July 2024), with any concurrent request for a one-time 12 month no-cost extension (if applicable) subject to review by the Survivorship Program along with a final progress report at the end of any no-cost extension.
- Additional reporting of any papers and future grants derived from this pilot award may be requested annually by the Cancer Consortium for up to 5 years following the completion of the funded project.
- Expectation of presenting one's study, preliminary results at the Fred Hutch Late Effects Affinity Group seminar series (to be scheduled in coordination with the seminar series once awarded).